- Home
- BARK vs AVIR Comparison
BARK vs AVIR Comparison
Compare BARK & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BARK | AVIR |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | 55 |
| Industry | Department/Specialty Retail Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.7M | 450.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BARK | AVIR |
|---|---|---|
| Price | $0.64 | $5.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $2.50 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 589.8K | 574.1K |
| Earning Date | 02-05-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $2.46 |
| 52 Week High | $1.48 | $6.45 |
Technical Indicators
Market Signals| Indicator | BARK | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 29.97 | 60.65 |
| Support Level | $0.53 | $3.33 |
| Resistance Level | $0.66 | $6.45 |
| Average True Range (ATR) | 0.04 | 0.34 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 13.00 | 58.86 |
Price Performance
Historical ComparisonAbout BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.